subscribeSubscribe
price-trendAsk Us
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS

Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS
PRNEWSWIRE
15 Nov 2021
Share Share
Biohaven`s CNS drug from AstraZeneca fails phase 3 trial

Biohaven`s CNS drug from AstraZeneca fails phase 3 trial
M. Maddipatla REUTERS
28 Sep 2021
Share Share
Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform

Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform
PRESS RELEASE
03 Aug 2020
Share Share
Biohaven Completes Enrollment Ahead Ph3 Clinical Trial of Verdiperstat

Biohaven Completes Enrollment Ahead Ph3 Clinical Trial of Verdiperstat
PRNEWSWIRE
21 Jul 2020
Share Share
Biohaven`s Verdiperstat Receives Fast Track Designation

Biohaven`s Verdiperstat Receives Fast Track Designation
PRNEWSWIRE
18 Mar 2020
Share Share
Biohaven Enrolls First Patient In Pha3 Clinical Trial Of Verdiperstat

Biohaven Enrolls First Patient In Pha3 Clinical Trial Of Verdiperstat
PR NEWSWIRE
31 Jul 2019
Share Share
Biohaven`s Verdiperstat Receives Orphan Drug Designation From FDA For MSA

Biohaven`s Verdiperstat Receives Orphan Drug Designation From FDA For MSA
PR NEWSWIRE
19 Feb 2019
Share Share
Biohaven picks up AstraZeneca CNS drug, plans phase 3

Biohaven picks up AstraZeneca CNS drug, plans phase 3
Nick Paul Taylor FIERCE BIOTECH
07 Sep 2018
Share Share
After rare disease failure, Biohaven pushes the gas on oral migraine drug

After rare disease failure, Biohaven pushes the gas on oral migraine drug
Phil Taylor FIERCE BIOTECH
27 Nov 2017
Share Share